Pharma

Rupee's fall to boost IT & Pharma, but is it too soon to bet? Analysts weigh in

India’s rupee has fallen to a new low against the US dollar, raising concerns across markets. But analysts say not everyone loses.

Lupin to invest $250 mn in new US facility for critical respiratory drugs

Drug firm Lupin on Wednesday said it will set up a new manufacturing facility in Coral Springs, Florida, entailing an investment of USD 250 million. With a projected cumulative investment of USD 250 million, including research & development, infrastructure and capital expenditures over a five-year period, the new site will have the capacity to accommodate the production of more than 25 critical respiratory medicines, the Mumbai-based drug maker said in a regulatory filing. The Florida-based plant would produce products like albuterol inhalers for children with asthma, it added. By strengthening domestic manufacturing and enhancing supply chain diversification, this critical project will enhance medicine security and strengthen the company's position as a global respiratory leader, it said. Locally, the infrastructure will generate over 200 new long-term, skilled jobs by 2030 in Broward County. "The expansion of Lupin's footprint in Coral Springs is a core part of our growth ...

Trump’s 100% tariff shock on pharma: What it means for India, pharma stocks?

US President Donald Trump has once again rattled markets with his tariff announcement, this time targeting the pharmaceutical sector.

NPPA asks pharma firms to pass on GST rate cut benefits from Sept 22

The National Pharmaceutical Pricing Authority has asked pharmaceutical companies and medical device makers to pass on the benefit of reduced GST rates to consumers with effect from September 22. "The benefit of reduction in GST rates shall be passed on to consumers/patients effective from September 22, 2025. All the manufacturers /marketing companies selling drugs/formulations shall revise theP of drugs/formulations (including medical devices) accordingly, with effect from September 22," the authority said in an order. The manufacturer and marketing companies shall issue a revised price list or supplementary price list to the dealers, retailers, state drug controllers and the government, reflecting the revised GST rates and revisedP, the National Pharmaceutical Pricing Authority (NPPA) stated. Manufacturer and marketing companies shall take immediate measures to sensitise dealers, retailers, and consumers about the reduction in GST rates through all possible channels of communicatio

New data shows just how powerful the next weight-loss drugs may be

The drugs in development include a pill that a new trial suggests is about as effective as Ozempic

OneSource eyes weight-loss drug boost to order book

Global drugmakers, including generic drug manufacturers in India, are racing to develop their versions of blockbuster injectable obesity drugs from Denmark's Novo Nordisk and U.S.-based Eli Lilly

Pharma body seeks rethink on entry curbs of MRs in govt hospitals

Indian Pharmaceutical Alliance warns that the DGHS ban on medical representatives may affect public health, slow innovation and result in pharma sector job losses

Venus Remedies gets GMP renewal certification from Ukraine's SMDC

Pharma major Venus Remedies on Saturday said it has successfully renewed its good manufacturing practices (GMP) certification from Ukraine's State Service on Medicines and Drugs Control (SMDC). The certification applies to the company's Unit-II manufacturing facility located in Baddi, Himachal Pradesh, covering its cephalosporin, non-cephalosporin (carbapenem), and oncology parenteral production lines, including liquid and lyophilized injections, Venus Remedies said in a statement. "Renewal of the Ukrainian GMP certification underlines our unwavering commitment to maintaining world-class manufacturing standards. This milestone not only reinforces our foothold in the Ukrainian market but also facilitates deeper penetration into PIC/S markets, significantly enhancing our international growth prospects," Venus Remedies President, Global Critical Care, Saransh Chaudhary said. Ukraine, being a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consortium, comprising 56 .

Spurious batch of Telma H flagged, 103 other drugs fail CDSCO tests

Telma H is manufactured by Glenmark Pharmaceuticals and is prescribed for controlling high blood pressure, particularly in individuals prone to water retention or heart failure

NPPA revises ceiling prices for over 900 drug formulations from April 1

With the changes, manufacturers will be allowed to increase the maximum retail price (MRP) of scheduled formulations on the basis of WPI without needing any prior approval from the government

US prosecutors investigate tip about timing of Pfizer's Covid vaccine

The report said on Wednesday GSK's former head of vaccine development, Philip Dormitzer, had told his colleagues about the delay by Pfizer, where he worked before joining the British company

Drugmakers Mallinckrodt, Endo agree to merge in nearly $7 billion deal

Endo shareholders will get $80 million in cash and own 49.9 per cent of the combined company, while Mallinckrodt shareholders will own the rest for an enterprise value of $6.7 billion

Indian pharma market registers over 8% growth in January 2025: Pharmarack

Among them, the cardiac, anti-diabetic, and gastrointestinal therapies saw high value growth of 10.9 per cent, 10.2 per cent, and 6.9 per cent, respectively, driving overall IPM growth

Pharma dept reprimands AbbVie Healthcare for unethical marketing practices

Company sponsored 'extravagant pleasure trips' abroad of 30 doctors, violating code on pharmaceutical marketing practices

Swiss PE eyes IT, pharma in India portfolio rejig after 300% gain

The fund is looking to exit some India investments and deploy the winnings in other sectors in the country such as healthcare, technology, education and shadow lending

Blackstone, Bain to bid for Mitsubishi pharma unit in up to $3.5 bn deal

Mitsubishi Chemical has hired Goldman Sachs to run the sale process and binding bids are due on Dec. 24, the sources said

CDMO player OneSource expands GLP-1 drug-device capacity as demand soars

OneSource Specialty Pharma recently raised Rs 801 crore through equity issuance

Six pharma companies sign MoUs with Telangana govt for Pharma City

Six prominent pharmaceutical companies, including Dr Reddy's Laboratories, Aurobindo Pharma, and Hetero Labs, have signed memorandums of understanding (MoUs) with the Telangana government to set up facilities in the Pharma City near here, the government announced on Friday. The companies have committed to invest over Rs 5,260 crore, which is expected to create 12,490 job opportunities in the pharma sector, according to an official release. Representatives from the companies met with Chief Minister A Revanth Reddy and Industries Minister D Sridhar Babu at the Secretariat to finalise the agreements. "The pharma company managements signed MoUs to establish the industries. The six companies expressed their interest to invest more than Rs 5260 crore. The investments will provide 12,490 job opportunities in the pharma sector. The government will allocate land for the establishment of the new pharma manufacturing units in the recognised pharma city, the release said. According to the MoUs

Indian pharma market registers over 5% growth in Sept 2024: Pharmarack

This comes even as the IPM registered a negative unit growth of -2.3 per cent, with only anti-diabetic and urology therapy segments recording significant unit growth of 3.1 per cent and 5.4 per cent

Pharmaceutical firms up their game to crackdown on spurious drugs

The concluding part of the series delves into strategies being applied by leading drug firms to battle counterfeits